Colesevelam hydrochloride: A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus

Prasanth N Surampudi, Prathima Nagireddy, Vivian A. Fonseca

Research output: Contribution to journalReview article

1 Scopus citations


The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrochloride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.

Original languageEnglish (US)
Pages (from-to)475-487
Number of pages13
Issue number4
StatePublished - Jul 2009
Externally publishedYes



  • Bile acid sequestrants
  • Colesevelam HCl
  • Farnesoid X receptor
  • Glycemic control
  • Low-density lipoprotein cholesterol
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this